Europe Radiopharmaceuticals Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2024 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 3,487.24 |
 CAGR |
% |
| Major Markets Players |
Europe Radiopharmaceuticals Market, By Type (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), Application (Diagnostic and Therapeutic), Source (Nuclear reactors and Cyclotrons), End User (Hospitals, Diagnostic Centers, Cancer research institutes, Ambulatory surgical centers, and Others) - Industry Trends and Forecast to 2030.
Europe Radiopharmaceuticals Market Analysis and Insights
The increasing awareness about radiopharmaceuticals in Europe has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of drug development techniques also contributes to the rising demand for radiopharmaceuticals.
The Europe radiopharmaceuticals market is expected to grow due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing growth in the field of drug development is further boosting the market growth. However, difficulties such as the lack of standardized protocols and the lack of skilled professionals are expected to restrain the market growth.
The increasing healthcare expenditure on advancement and drug development is expected to give opportunities to the market. However, the growing use of alternative treatments may challenge market growth.
Data Bridge Market Research analyzes that the Europe radiopharmaceuticals market is expected to reach a value of USD 3,487.24 million by 2030, at a CAGR of 5.9% during the forecast period of 2023-2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2015 – 2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
Type (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals), Application (Diagnostic and Therapeutic), Source (Nuclear reactors and Cyclotrons), End User (Hospitals, Diagnostic Centers, Cancer research institutes, Ambulatory surgical centers, and Others) |
|
Countries Covered |
Germany, U.K., France, Italy, Spain, Belgium, Poland, Russia, Norway, Turkey, Austria, Ireland, Hungary, Netherlands, Switzerland, and Rest of Europe |
|
Market Players Covered |
Cardinal Health, Advanced Accelerator Applications, A Novartis Company, Lantheus, CURIUM, Jubilant Radiopharma A Jubilant Pharmova Company, China lsotope & Radiation Corporation., Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide, Institute of Isotopes among others |
Europe Radiopharmaceuticals Market Definition
A radiopharmaceutical contains a radioactive substance in association with one or more ingredients that are intended to diagnose, stage a disease, monitor treatment, or provide therapy. Radiopharmaceuticals include a group of radioactive agents used for either diagnostic or therapeutic interventions. These are the pharmaceuticals that incorporate a radionuclide. Most radiopharmaceuticals are a combination of a radioactive nuclide or radionuclide, and a biologically active molecule or drug that acts as a carrier and determines localization and biodistribution.
Europe Radiopharmaceuticals Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- The Growing Demand for Radiopharmaceuticals in Diagnostics and Clinical Use
Radiopharmaceuticals have become essential in helping to diagnose organs and treat pathological disorders. They are utilized in diagnostic imaging and radiotherapy. Diagnostic radiopharmaceuticals possess no pharmacological effects and their administration is also not considered to be associated with relevant clinical side effects.
The number of radiopharmaceuticals in clinical use is rapidly growing, thus, allowing the medical community better access to detailed information on the characteristics of the different types of tumors. Radionuclides are also gaining importance by providing palliative and curative treatment for an increasing number of malignant diseases.
Opportunity
- The Rising Research and Development Expenditure of Radiopharmaceuticals
Technological advancements include enhancing the stability and strength of traditional pharmaceuticals. The biotechnology and pharma companies are continuously investing in research and development to offer innovative services for diagnostics as well as medications to the customers and enhance their market presence. Radiopharmaceuticals play a dynamic role in clinical development. While the diagnostic industry is in a constant state of fluctuation due to the implementation of new technologies in the market, the pharmaceutical and biotechnology industries continue to increase due to enhanced investment in radiopharmaceutical companies along with mergers and acquisitions adoption of innovation in imaging technologies to support clinical trials for various diseases.
The increasing research and development expenditure in pharmaceutical and biotechnological companies is acting as an opportunity for the growth of the Europe radiopharmaceuticals market.
Restraints/Challenges
- Stringent Regulations for Radiopharmaceuticals
Radiopharmaceuticals are agents used to diagnose certain medical problems or treat certain diseases. Therefore, the various types of government regulations for launching a product in the market are found to be a big restraint. Every country has its regulations and has different bodies for regulatory procedures. Stringent regulatory and product approval policies are expected to hinder the development of the radiopharmaceuticals market.
The stringent regulations from the government authorities are necessary to safeguard the company's reputation, prevent products from being unreliable, and increase trust on the side of consumers. There are several stages of investment and testing to gain approval from the regulated authority for a new drug which is comprised of various phases and each phase has different regulatory requirements.
The organization conducting the trial needs to comply with the required documentation by the specific regulatory authority of the concerned country and should be safe and legal as per the country's policies and jurisdiction.
However, the stringent regulatory guidelines for regulating the radiopharmaceuticals in the market may hinder the market growth, and the withdrawals of the drug from the market due to complex regulation can negatively impact the market which is expected to restrain the market growth.
- High Cost of Development and Implementation of Radiopharmaceuticals
Radiopharmaceuticals play an important role in healthcare facilities, providing safety and efficiency in pharmaceutical and biotechnology companies. They have excellent properties and some disadvantages at the same time. Radiopharmaceuticals are expected to grow due to advancements in technology. However, several obstacles may prevent the market from realizing its full potential as radiopharmaceuticals are expensive to develop and implement, and the market may not be expanding rapidly. Thus, higher development and implementation costs and requirements for suitable surfaces are limiting the market growth, resulting in additional infrastructure and operational costs.
Recent Developments
- In October 2023, IBA launched AKURACY which is an integrated solution for cardiac pet imaging at each meeting in Barcelona. The company believes and states that this is a unique integrated solution for pet myocardial perfusion imaging.
- In April 2023, Lantheus and POINT Biopharma announced FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. The company stated that radioligand therapy is quickly becoming another pillar of cancer treatment.
Europe Radiopharmaceuticals Market Scope
The Europe radiopharmaceuticals market is segmented into four notable segments such as type, application, source, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
On the basis of type, the market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals.
Application
- Diagnostic
- Therapeutic
On the basis of application, the market is segmented into diagnostic and therapeutic.
Source
- Nuclear reactors
- Cyclotrons
On the basis of source, the market is segmented into nuclear reactors and cyclotrons.
End User
- Hospitals
- Diagnostic Centers
- Cancer research institutes
- Ambulatory surgical centers
- Others
On the basis of end user, the market is segmented into hospitals, diagnostic centers, cancer research institutes, ambulatory surgical centers, and others.
Europe Radiopharmaceuticals Market Regional Analysis/Insights
The Europe radiopharmaceuticals market is segmented into four notable segments such as type, application, source, and end user.
The countries covered in this market report are Germany, U.K., France, Italy, Spain, Belgium, Poland, Russia, Norway, Turkey, Austria, Ireland, Hungary, Netherlands, Switzerland, and Rest of Europe.
Germany is expected to dominate the market due to the increasing investment in the healthcare sector, which is expected to boost market growth. Germany is expected to dominate the Europe region due to the rise in technological advancement in healthcare and treatment products.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Radiopharmaceuticals Market Share Analysis
The Europe radiopharmaceuticals market market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the Europe radiopharmaceuticals market are Cardinal Health, Advanced Accelerator Applications, A Novartis Company, Lantheus, CURIUM, Jubilant Radiopharma A Jubilant Pharmova Company, China lsotope & Radiation Corporation., Siemens Healthcare GmbH, Bracco, Eckert & Ziegler, SHINE Technologies, LLC, IBA Worldwide, Institute of Isotopes among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
4.4 PATENT ANALYSIS
4.5 DRUG TREATMENT RATE BY MATURED MARKETS
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.7 PATIENT FLOW DIAGRAM
4.8 KEY PRICING STRATEGIES
4.9 KEY PATIENT ENROLLMENT STRATEGIES
5 LIST OF CYCLOTRONS
5.1 EUROPE
6 REGULATORY SCENARIO
6.1 EUROPE
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
7.3 OPPORTUNITIES
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
7.4 CHALLENGES
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
8 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 PET
9.2.1.1 ONCOLOGY
9.2.1.2 CARDIOLOGY
9.2.1.3 NEUROLOGY
9.2.1.4 OTHER PET APPLICATION
9.2.2 SPECT
9.2.2.1 CARDIOLOGY
9.2.2.2 BONE SCANS
9.2.2.3 THYROID APPLICATIONS
9.2.2.4 PULMONARY SCANS
9.2.2.5 OTHER SPECT APPLICATION
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
11 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTIC CENTERS
11.4 CANCER RESEARCH INSTITUTES
11.5 AMBULATORY SURGICAL CENTERS
11.6 OTHERS
12 EUROPE RADIOPHARMACEUTICAL MARKET
12.1 EUROPE
12.1.1 GERMANY
12.1.2 U.K.
12.1.3 FRANCE
12.1.4 ITALY
12.1.5 SPAIN
12.1.6 BELGIUM
12.1.7 POLAND
12.1.8 RUSSIA
12.1.9 NORWAY
12.1.10 TURKEY
12.1.11 AUSTRIA
12.1.12 IRELAND
12.1.13 HUNGARY
12.1.14 NETHERLANDS
12.1.15 SWITZERLAND
12.1.16 REST OF EUROPE
13 COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 GENERAL ELECTRIC COMPANY
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 BRACCO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.7 CHINA ISOTOPE & RADIATION CORPORATION
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ECKERT & ZIEGLER
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 IBA WORLDWIDE
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 INSTITUTE OF ISOTOPES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 SHINE TECHNOLOGIES, LLC
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 SIEMENS HEALTHCARE GMBH
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 3 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 16 EUROPE RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 17 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 21 EUROPE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 22 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 24 EUROPE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 25 EUROPE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 28 EUROPE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 29 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 31 EUROPE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 32 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 34 EUROPE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 35 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 41 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 42 GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 43 GERMANY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 45 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 46 GERMANY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 47 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 49 GERMANY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 50 GERMANY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 53 GERMANY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 54 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 55 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 56 GERMANY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 57 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 58 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 59 GERMANY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 60 GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 GERMANY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 GERMANY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 GERMANY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 GERMANY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 GERMANY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 66 GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 67 U.K. RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.K. DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 71 U.K. PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 72 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 73 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 74 U.K. SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 75 U.K. THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 76 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 77 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 78 U.K. BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 79 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 80 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 81 U.K. BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 82 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 84 U.K. ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 85 U.K. RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 86 U.K. DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 87 U.K. PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 88 U.K. SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 89 U.K. THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 90 U.K. RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 91 U.K. RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 FRANCE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 FRANCE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 94 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 96 FRANCE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 97 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 99 FRANCE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 100 FRANCE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 103 FRANCE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 104 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 105 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 106 FRANCE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 107 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 108 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 109 FRANCE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 110 FRANCE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 111 FRANCE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 112 FRANCE PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 113 FRANCE SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 114 FRANCE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 115 FRANCE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 116 FRANCE RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 117 ITALY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 118 ITALY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 119 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 121 ITALY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 122 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 124 ITALY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 125 ITALY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 126 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 127 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 128 ITALY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 129 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 131 ITALY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 132 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 134 ITALY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 135 ITALY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 ITALY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 ITALY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 ITALY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 ITALY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 ITALY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 141 ITALY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 SPAIN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 143 SPAIN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 146 SPAIN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 147 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 149 SPAIN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 150 SPAIN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 152 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 153 SPAIN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 154 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 156 SPAIN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 157 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 158 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 159 SPAIN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 160 SPAIN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 SPAIN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 SPAIN PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 SPAIN SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 164 SPAIN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 SPAIN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 166 SPAIN RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 167 BELGIUM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 168 BELGIUM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 169 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 170 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 171 BELGIUM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 172 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 173 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 174 BELGIUM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 175 BELGIUM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 178 BELGIUM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 179 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 180 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 181 BELGIUM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 182 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 183 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 184 BELGIUM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 185 BELGIUM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 BELGIUM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 187 BELGIUM PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 BELGIUM SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 189 BELGIUM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 190 BELGIUM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 191 BELGIUM RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 POLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 POLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 194 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 195 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 196 POLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 197 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 198 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 199 POLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 200 POLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 201 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 202 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 203 POLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 204 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 206 POLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 207 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 209 POLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 210 POLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 211 POLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 212 POLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 POLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 POLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 POLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 216 POLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 RUSSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 221 RUSSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 222 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 224 RUSSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 225 RUSSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 228 RUSSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 229 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 231 RUSSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 232 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 233 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 234 RUSSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 235 RUSSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 236 RUSSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 RUSSIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 238 RUSSIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 239 RUSSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 240 RUSSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 241 RUSSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 NORWAY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 NORWAY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 244 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 245 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 246 NORWAY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 247 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 248 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 249 NORWAY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 250 NORWAY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 253 NORWAY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 254 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 255 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 256 NORWAY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 257 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 258 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 259 NORWAY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 260 NORWAY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 NORWAY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 NORWAY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 NORWAY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 264 NORWAY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 265 NORWAY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 266 NORWAY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 267 TURKEY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 TURKEY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 269 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 270 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 271 TURKEY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 272 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 274 TURKEY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 275 TURKEY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 276 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 278 TURKEY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 279 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 281 TURKEY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 282 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 284 TURKEY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 285 TURKEY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 286 TURKEY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 287 TURKEY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 TURKEY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 TURKEY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 TURKEY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 291 TURKEY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 293 AUSTRIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 295 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 296 AUSTRIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 297 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 299 AUSTRIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 300 AUSTRIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 301 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 302 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 303 AUSTRIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 304 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 306 AUSTRIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 307 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 309 AUSTRIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 310 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 AUSTRIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 312 AUSTRIA PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 313 AUSTRIA SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 314 AUSTRIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 315 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 316 AUSTRIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 317 IRELAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 318 IRELAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 319 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 320 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 321 IRELAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 322 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 323 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 324 IRELAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 325 IRELAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 328 IRELAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 329 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 331 IRELAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 332 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 333 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 334 IRELAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 335 IRELAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 IRELAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 IRELAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 IRELAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 IRELAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 IRELAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 341 IRELAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 HUNGARY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 HUNGARY DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 346 HUNGARY PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 347 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 348 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 349 HUNGARY SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 350 HUNGARY THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 351 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 352 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 353 HUNGARY BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 354 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 355 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 356 HUNGARY BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 357 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 359 HUNGARY ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 360 HUNGARY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 361 HUNGARY DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 362 HUNGARY PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 363 HUNGARY SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 364 HUNGARY THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 HUNGARY RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 366 HUNGARY RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 368 NETHERLANDS DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 369 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 371 NETHERLANDS PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 372 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 374 NETHERLANDS SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 375 NETHERLANDS THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 378 NETHERLANDS BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 379 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 381 NETHERLANDS BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 382 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 384 NETHERLANDS ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 385 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 392 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 393 SWITZERLAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 394 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 395 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 396 SWITZERLAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 397 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 399 SWITZERLAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 400 SWITZERLAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 403 SWITZERLAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 404 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 406 SWITZERLAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP IN MBQ)
TABLE 407 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (VOLUME IN MBQ)
TABLE 409 SWITZERLAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (ASP PER MBQ)
TABLE 410 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND PET IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND SPECT IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 417 REST OF EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE RADIOPHARMACEUTICALS: SEGMENTATION
FIGURE 2 EUROPE RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE RADIOPHARMACEUTICALS MARKET: MARKET TYPE COVERAGE GRID
FIGURE 9 EUROPE RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 10 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 11 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE RADIOPHARMACEUTICALS MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE RADIOPHARMACEUTICALS MARKET
FIGURE 13 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2022
FIGURE 14 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2022
FIGURE 18 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 19 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 20 EUROPE RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 21 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2022
FIGURE 22 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023-2030 (USD MILLION)
FIGURE 23 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2023-2030)
FIGURE 24 EUROPE RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 25 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2022
FIGURE 26 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 27 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 28 EUROPE RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2022)
FIGURE 30 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022)
FIGURE 31 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 32 EUROPE RADIOPHARMACEUTICALS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 33 EUROPE RADIOPHARMACEUTICALS MARKET: BY TYPE (2023-2030)
FIGURE 34 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
